Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Endoplasmic reticulum mannosyl-oligosaccharide 1,2-alpha-mannosidase (ERMan1)
- Target
- ERMan1
- Molecular classification
- Enzyme, Glycoside hydrolase family 47[1][2][5][7]
01
Overview
Endoplasmic reticulum mannosyl-oligosaccharide 1,2-alpha-mannosidase (ERMan1; encoded by MAN1B1) is an enzyme of glycoside hydrolase family 47 responsible for trimming a single alpha-1,2-linked mannose from the Man9GlcNAc2 oligosaccharide during N-glycan maturation in the endoplasmic reticulum. This trimming marks misfolded glycoproteins for degradation via the ER-associated degradation pathway, contributing critically to protein quality control. ERMan1 is considered a potential antiviral target, as its inhibition disrupts glycoprotein maturation and reduces viral infectivity in some models[1][2][4][5][6][7].
- Other names
- ER alpha-1,2-mannosidaseER mannosidase 1ERMan1Man9GlcNAc2-specific-processing alpha-mannosidaseMannosidase alpha class 1B member 1MAN1B1[5][7]
02
Mechanism of action
Inhibition of ERMan1 disrupts the maturation of N-glycans and enhances retention and degradation of misfolded glycoproteins; Inhibition can block viral glycoprotein maturation, reducing viral infectivity[4][6]
03
Biological functions
Glycoprotein quality controlProtein foldingN-glycan maturationRemoval of misfolded glycoproteinsOligosaccharide metabolic process[2][5][7]
04
Disease associations
Congenital disorders of glycosylationCancerViral infection[4][6]
05
Safety considerations
Potential disruption of general protein quality control and ER-associated degradation (ERAD), leading to accumulation of misfolded proteinspossible effect on normal cell viability and function[5][7]
06
Interacting drugs
No clinically approved drugs directly targeting this enzyme are currently listed
1 more in the full profile.
07
Biomarkers
Impaired glycoprotein processing can be monitored by N-glycan profilesMAN1B1 mutations are biomarkers in certain congenital disorders of glycosylation[5][7]
Beyond the preview
Go deeper on Endoplasmic reticulum mannosyl-oligosaccharide 1,2-alpha-mannosidase (ERMan1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Endoplasmic reticulum mannosyl-oligosaccharide 1,2-alpha-mannosidase (ERMan1).